Model‐Based Evaluation of Proximal Sodium Reabsorption Through SGLT2 in Health and Diabetes and the Effect of Inhibition With Canagliflozin
- 16 November 2017
- journal article
- research article
- Published by Wiley in The Journal of Clinical Pharmacology
- Vol. 58 (3) , 377-385
Abstract
Sodium‐glucose cotransporter 2 inhibitors (SGLT2i) reduce glucose levels in diabetes by inhibiting renal glucose reabsorption in the proximal tubule (PT), resulting in urinary glucose excretion. A recent large cardiovascular outcomes trial suggested that the SGLT2i empagliflozin may also decrease risk of renal dysfunction. Because sodium (Na) and glucose reabsorption are coupled through SGLT2, it is hypothesized that the renal benefits may be derived from lowering Na reabsorption in the PT, which would lead to favorable renal hemodynamic changes. However, the quantitative contribution of SGLT2 to PT Na reabsorption, as well as the differences between healthy and diabetic subjects, and the impact of SGLT2i on PT Na reabsorption are unknown. In this study we extended an existing mathematical model of glucose dynamics to account for renal glucose filtration and excretion. We utilized this model to quantify glucose and Na reabsorption through SGLT2 in healthy, controlled, and uncontrolled diabetes and following treatment with canagliflozin. In healthy, controlled diabetic, and uncontrolled diabetic states, Na reabsorption through SGLT2 was found to be 5.7%, 11.5%, and 13.7% of total renal Na reabsorption, and 7.1% to 9.5%, 14.4% to 19.2%, and 17.1% to 22.8% of sodium reabsorption in the PT alone. The model predicted that treatment of controlled diabetes with canagliflozin returns PT Na reabsorption through SGLT2 to normal levels. The degree of increased PT Na reabsorption due to SGLT2 is likely sufficient to drive pathologic changes in renal hemodynamics, and restoration of normal Na reabsorption through SGLT2 may contribute to beneficial renal effects of SGLT2 inhibition.Keywords
This publication has 13 references indexed in Scilit:
- Predicted consequences of diabetes and SGLT inhibition on transport and oxygen consumption along a rat nephronAmerican Journal of Physiology-Renal Physiology, 2016
- Rapid GFR decline is associated with renal hyperfiltration and impaired GFR in adults with Type 1 diabetesNephrology Dialysis Transplantation, 2015
- Pharmacokinetics and Pharmacodynamics of Canagliflozin, a Sodium Glucose Co‐Transporter 2 Inhibitor, in Subjects With Type 2 Diabetes MellitusThe Journal of Clinical Pharmacology, 2013
- Renal Function in Diabetic Disease Models: The Tubular System in the Pathophysiology of the Diabetic KidneyAnnual Review of Physiology, 2012
- Canagliflozin, a novel inhibitor of sodium glucose co‐transporter 2, dose dependently reduces calculated renal threshold for glucose excretion and increases urinary glucose excretion in healthy subjectsDiabetes, Obesity and Metabolism, 2011
- Modeling of 24-Hour Glucose and Insulin Profiles of Patients With Type 2 DiabetesThe Journal of Clinical Pharmacology, 2011
- An Integrated Glucose‐Insulin Model to Describe Oral Glucose Tolerance Test Data in Type 2 DiabeticsThe Journal of Clinical Pharmacology, 2007
- An Integrated Model for Glucose and Insulin Regulation in Healthy Volunteers and Type 2 Diabetic Patients Following Intravenous Glucose ProvocationsThe Journal of Clinical Pharmacology, 2007
- Glomerular Hyperfiltration and the Salt Paradox in Early Type 1 Diabetes MellitusJournal of the American Society of Nephrology, 2003
- Renal hemodynamics and segmental tubular reabsorption in early type 1 diabetesKidney International, 1990